{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:29:51Z","timestamp":1789586991389,"version":"build-2803163510"},"reference-count":182,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S70720N"],"award-info":[{"award-number":["1S70720N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The challenging market access of high-cost one-time curative therapies has inspired the development of alternative reimbursement structures, such as outcome-based spread payments, to mitigate their unaffordability and answer remaining uncertainties. This study aimed to provide a broad overview of barriers and possible opportunities for the practical implementation of outcome-based spread payments for the reimbursement of one-shot therapies in European healthcare systems.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A systematic literature review was performed investigating published literature and publicly available documents to identify barriers and implementation opportunities for both spreading payments and for implementing outcome-based agreements. Data was analyzed via qualitative content analysis by extracting data with a reporting template.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 1,503 publications were screened and 174 were included. Main identified barriers for the implementation of spread payments are reaching an agreement on financial terms while considering 12-months budget cycles and the possible violation of corresponding international accounting rules. Furthermore, outcome correction of payments is currently hindered by the need for additional data collection, the lack of clear governance structures and the resulting administrative burden and cost. The use of spread payments adjusted by population- or individual-level data collected within automated registries and overseen by a governance committee and external advisory board may alleviate several barriers and may support the reimbursement of highly innovative therapies.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    High-cost advanced therapy medicinal products pose a substantial affordability challenge on healthcare systems worldwide. Outcome-based spread payments may mitigate the initial budget impact and alleviate existing uncertainties; however, their effective implementation still faces several barriers and will be facilitated by realizing the required organizational changes.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2020.594446","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T02:07:39Z","timestamp":1607393259000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies"],"prefix":"10.3389","volume":"11","author":[{"given":"Sissel","family":"Michelsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Nachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Van Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.stem.2016.08.012","article-title":"Overcoming challenges facing advanced therapies in the EU market","volume":"19","author":"Abou-El-Enein","year":"2016","journal-title":"Cell Stem Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1472-6963-10-153","article-title":"Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers","volume":"10","author":"Adamski","year":"2010","journal-title":"BMC Health Services Res."},{"key":"B3","article-title":"Getting ready: recommendations for timely access to advanced therapy medicinal products (ATMPs) in Europe","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.18553\/jmcp.2017.17342","article-title":"AMCP partnership Forum: advancing value-based contracting","volume":"23","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.18553\/jmcp.2019.25.2.156","article-title":"AMCP partnership forum designing benefits and payment models for innovative high-investment medications","volume":"25","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B6","first-page":"1","volume-title":"Dynamic outcomes based approaches to pricing and reimbursement of innovative medicines.","author":"Annemans","year":"2017"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s40273-019-00838-w","article-title":"The use of risk-sharing contracts in healthcare: theoretical and empirical assessments","volume":"37","author":"Antonanzas","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40273-018-0619-4","article-title":"Personalized medicine and pay for performance: should pharmaceutical firms be fully penalized when treatment fails?","volume":"36","author":"Antonanzas","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"B9","unstructured":"AveXis announces innovative Zolgensma\u00ae gene therapy access programs for US payers and families2019"},{"key":"B10","first-page":"39","article-title":"Health plans and drug companies dip their toes into value-based pricing: the pressure is on P&T committees to monitor utilization","volume":"41","author":"Barlas","year":"","journal-title":"P T"},{"key":"B11","first-page":"562","article-title":"Value purchasing programs make plodding progress: drug manufacturers question some pay-for-performance methodologies","volume":"41","author":"Barlas","year":"","journal-title":"P T"},{"key":"B12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jval.2018.12.004","article-title":"Are payers ready, willing, and able to provide access to new durable gene therapies?","volume":"22","author":"Barlow","year":"2019","journal-title":"Value Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/14737167.2015.990887","article-title":"Financing cures in the United States","volume":"15","author":"Basu","year":"2015","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"A17","DOI":"10.1016\/j.jval.2014.03.112","article-title":"Real-world clinical evidence development: an analysis of relevant international models for the potential implementation of such a program in quebec","volume":"17","author":"Bibeau","year":"2014","journal-title":"Value Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"b4677","DOI":"10.1136\/bmj.b4677","article-title":"Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator","volume":"339","author":"Boggild","year":"2009","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fphar.2018.00280","article-title":"Managed entry agreements for pharmaceuticals in the context of adaptive pathways in Europe","volume":"9","author":"Bouvy","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2008.15","article-title":"Risk sharing and payment by results","volume":"83","author":"Breckenridge","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nbt.3003","article-title":"The special case of gene therapy pricing","volume":"32","author":"Brennan","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"B19","first-page":"33","article-title":"Payer and pharmaceutical manufacturer considerations for outcomes-based agreements in the United States. Value in health : the","volume":"21","author":"Brown","year":"2018","journal-title":"J. Int. Soc. Pharmacoeconom. Outcomes Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2146\/ajhp160398","article-title":"Emerging roles for pharmacists in performance-based risk-sharing arrangements","volume":"74","author":"Calabrese","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s40273-017-0535-z","article-title":"Performance-based risk-sharing arrangements: an updated international review","volume":"35","author":"Carlson","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.18553\/jmcp.2009.15.8.683","article-title":"Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals","volume":"15","author":"Carlson","year":"2009","journal-title":"J. Manag. Care Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"A359","DOI":"10.1007\/s40258-014-0093-x","article-title":"Current status and trends in performance-based schemes between health care payers and manufacturers","volume":"14","author":"Carlson","year":"2011","journal-title":"Value Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","article-title":"Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers","volume":"96","author":"Carlson","year":"2010","journal-title":"Health Policy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1016\/j.jval.2018.09.1249","article-title":"The future of value-based contracting for high-cost innovative therapies: global lessons from Europe and the US","volume":"21","author":"Carr","year":"2018","journal-title":"Value Health"},{"key":"B26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2217\/rme-2016-0010","article-title":"Gene therapies: the challenge of super-high-cost treatments and how to pay for them","volume":"11","author":"Carr","year":"2016","journal-title":"Regen. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"A500","DOI":"10.1016\/j.jval.2016.09.891","article-title":"A risk-benefit analysis of key performance-based risk sharing agreements (PBRSAs) in the EU and US (2002\u20132016)","volume":"19","author":"Carroll","year":"2016","journal-title":"Value Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"A481","DOI":"10.1016\/j.jval.2017.02.003","article-title":"Payer and patient perceptions of medication value and the role of patient-reported outcomes","volume":"15","author":"Cascade","year":"2012","journal-title":"Value Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/bmj.326.7391.707","article-title":"Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care","volume":"326","author":"Chapman","year":"2003","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2016.1215991","article-title":"Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer","volume":"20","author":"Clopes","year":"2017","journal-title":"J. Med. Econ."},{"key":"B31","volume-title":"Making outcome-based payment a reality in the NHS.","author":"Cole","year":"2019"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/j.ehrm.2012.07.002","article-title":"Outcomes-based risk-sharing schemes: is there a potential role in the asia-pacific markets?","volume":"3","author":"Coulton","year":"2012","journal-title":"Health Outcomes Res. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"A229","DOI":"10.1016\/S1098-3015(10)74116-4","article-title":"Designing and implementing outcome-based reimbursement schemes: experience from Hungary","volume":"12","author":"Dank\u00f3","year":"2009","journal-title":"Value Health"},{"key":"B34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jval.2017.12.018","article-title":"Affordability challenges to value-based pricing: mass diseases, orphan diseases, and cures","volume":"21","author":"Danzon","year":"2018","journal-title":"Value Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-006-0386-6","article-title":"Risk-sharing agreements for innovative drugs: a new solution to old problems?","volume":"7","author":"de Pouvourville","year":"2006","journal-title":"Eur. J. Health Econ."},{"key":"B36","doi-asserted-by":"publisher","first-page":"A273","DOI":"10.1016\/j.jval.2015.03.1592","article-title":"An innovative cloud-based platform for implementing performance-based risk-sharing arrangements (PBRSAs) in oncology settings","volume":"18","author":"De Rosa","year":"2015","journal-title":"Value Health"},{"key":"B37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jval.2019.03.012","article-title":"Analytic considerations in applying a general economic evaluation reference case to gene therapy","volume":"22","author":"Drummond","year":"2019","journal-title":"Value Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10198-015-0683-z","article-title":"When do performance-based risk-sharing arrangements make sense?","volume":"16","author":"Drummond","year":"2015","journal-title":"Eur. J. Health Econ."},{"key":"B39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s10198-015-0683-z","article-title":"The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey","volume":"24","author":"Duhig","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jval.2014.01.010","article-title":"Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?","volume":"17","author":"Edlin","year":"2014","journal-title":"Value Health"},{"key":"B41","volume-title":"Passing fad or game-changer? Outcomes-based contracting in life sciences","year":""},{"key":"B42","volume-title":"The missing piece - how EY\u2019s health outcomes platform can create \u201ctriple wins\u201d through outcomes-based contracting","year":""},{"key":"B43","volume-title":"Experiences and impact of European risk-sharing schemes focusing on oncology medicines","author":"Espin","year":"2011"},{"key":"B44","article-title":"Regulation (EC) No 1394\/2007 \u2013 on advanced therapy medicinal products and amending directive 2001\/83\/EC and regulation (EC) No 726\/2004","year":"2007"},{"key":"B45","volume-title":"Innovative payment models for high-cost innovative medicines","year":"2018"},{"key":"B46","article-title":"Ensuring patient access to regenerative and advanced therapies in managed care: how do we get there?","author":"Faulkner","year":"2018","journal-title":"J. Manag. Care Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cpt.508","article-title":"Pricing and reimbursement experiences and insights in the European Union and the United States: lessons learned to approach adaptive payer pathways","volume":"100","author":"Faulkner","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"S313","DOI":"10.1186\/s12961-018-0378-x","article-title":"PNS168 challenges in the design and implementation of coverage with development schemes for medical devices","volume":"22","author":"Federici","year":"2019","journal-title":"Value Health"},{"key":"B49","volume-title":"Managed entry agreements for pharmaceuticals: the European experience","author":"Ferrario","year":"2013"},{"key":"B50","doi-asserted-by":"publisher","first-page":"A360","DOI":"10.1016\/j.jval.2011.08.701","article-title":"Evidence on the impact of managed entries on payers, patients, manufacturers, and health care workers","volume":"14","author":"Ferrario","year":"2011","journal-title":"Value Health"},{"key":"B51","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/1468794113481790","article-title":"Use of content analysis to conduct knowledge-building and theory-generating qualitative systematic reviews","volume":"14","author":"Finfgeld-Connett","year":"2013","journal-title":"Qual. Res."},{"key":"B52","volume-title":"Payer perspectives on financing and reimbursement of one-time high-cost durable Treatments","year":""},{"key":"B53","volume-title":"Precision financing solutions for durable\/potentially curative therapies","year":""},{"key":"B54","volume-title":"Overcoming challenges of outcomes-based contracting for pharmaceuticals: early lessons from the genentech--priority health pilot","author":"Fox","year":"2017"},{"key":"B55","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jval.2013.12.009","article-title":"Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?","volume":"17","author":"Franken","year":"2014","journal-title":"Value Health"},{"key":"B56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1017\/S0266462311000079","article-title":"Risk sharing agreements: what lessons from Italy?","volume":"27","author":"Garattini","year":"2011","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10198-014-0585-5","article-title":"Italian risk-sharing agreements on drugs: are they worthwhile?","volume":"16","author":"Garattini","year":"2015","journal-title":"Eur. J. Health Econ."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMp078204","article-title":"Satisfaction guaranteed--\u201cpayment by results\u201d for biologic agents","volume":"357","author":"Garber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B59","first-page":"632","article-title":"Private sector risk-sharing agreements in the United States: trends, barriers, and prospects","volume":"21","author":"Garrison","year":"2015","journal-title":"Am. J. Manag. Care"},{"key":"B60","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","article-title":"Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force","volume":"16","author":"Garrison","year":"2013","journal-title":"Value Health"},{"key":"B61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fmed.2019.00043","article-title":"Real-world evidence gathering in oncology: the need for a biomedical big data insight-providing federated Network","volume":"6","author":"Geldof","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"B62","volume-title":"How to improve the Belgian process for managed entry agreements? An analysis of the Belgian and international experience","author":"Gerkens","year":"2017"},{"key":"B63","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/medlaw\/fwu005","article-title":"Niche markets and evidence assessment in transition: a critical review of proposed drug reforms","volume":"22","author":"Gibson","year":"2014","journal-title":"Med. Law Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.18553\/jmcp.2017.23.10.1042","article-title":"Performance-based risk-sharing arrangements: U.S. Payer experience","volume":"23","author":"Goble","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B66","doi-asserted-by":"publisher","first-page":"A30","DOI":"10.1016\/j.jval.2012.03.174","article-title":"The future of alternative pricing\/risk-sharing agreements in the United States","volume":"15","author":"Goldenberg","year":"2012","journal-title":"Value Health"},{"key":"B67","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.jval.2018.04.396","article-title":"The current landscape and future of outcomes-based contracting with commercial healthcare payers in the US","volume":"21","author":"Goldenberg","year":"2018","journal-title":"Value Health"},{"key":"B68","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3332\/ecancer.2018.823","article-title":"Risk-sharing agreements, present and future","volume":"12","author":"Gon\u00e7alves","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.18553\/jmcp.2019.19167","article-title":"Regulatory, policy, and operational considerations for outcomes-based risk-sharing agreements in the U.S. Market: opportunities for reform","volume":"25","author":"Goodman","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B70","volume-title":"Establishing new payment provisions for the high cost of curing disease","author":"Gottlieb","year":"2014"},{"key":"B71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2217\/cer-2017-0068","article-title":"Gene therapy: evidence, value and affordability in the US health care system","volume":"7","author":"Hampson","year":"2018","journal-title":"J. Comp. Eff. Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1265293","DOI":"10.1080\/20016689.2017.1265293","article-title":"Gene therapies development: slow progress and promising prospect","volume":"5","author":"Hanna","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"B73","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.healthpol.2017.11.012","article-title":"Funding breakthrough therapies: a systematic review and recommendation","volume":"122","author":"Hanna","year":"2018","journal-title":"Health Policy"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","article-title":"The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol. Assess."},{"key":"B75","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/d41573-020-00032-0","article-title":"A future for regulatory science in the European Union: the European Medicines Agency\u2019s strategy","volume":"19","author":"Hines","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B76","doi-asserted-by":"publisher","first-page":"A466","DOI":"10.1016\/j.jval.2018.08.007","article-title":"Determining the comparative value of outcome-based money-back guarantee scenarios in non-small cell lung cancer using real-world data","volume":"20","author":"Holleman","year":"2017","journal-title":"Value Health"},{"key":"B77","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1017\/S0266462307070651","article-title":"Coverage with evidence development: an examination of conceptual and policy issues","volume":"23","author":"Hutton","year":"2007","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B78","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.jval.2019.04.115","article-title":"PBI33 can innovative payment reform be the solution to address reimbursement and uptake challenges for CAR-T therapies?","volume":"22","author":"Infante","year":"2019","journal-title":"Value Health"},{"key":"B79","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2165\/11592960-000000000-00000","article-title":"Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence","volume":"9","author":"Jaroslawski","year":"","journal-title":"Appl. Health Econ. Health Pol."},{"key":"B80","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1472-6963-11-259","article-title":"Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts","volume":"11","author":"Jaroslawski","year":"","journal-title":"BMC Health Services Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10198-018-1007-x","article-title":"Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare","volume":"20","author":"J\u00f6nsson","year":"2019","journal-title":"Eur. J. Health Econ."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3402\/jmahp.v3.29321","article-title":"Reimbursement of licensed cell and gene therapies across the major European healthcare markets","volume":"30","author":"Jorgensen","year":"2015","journal-title":"J. Mark. Access Health Policy"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1355203","DOI":"10.1080\/20016689.2017.1355203","article-title":"Annuity payments can increase patient access to innovative cell and gene therapies under England\u2019s net budget impact test","volume":"5","author":"Jorgensen","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1635842","DOI":"10.1080\/20016689.2019.1635842","article-title":"Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate","volume":"7","author":"Jorgensen","year":"2019","journal-title":"J. Mark. Access Health Policy"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1573164","DOI":"10.1177\/0193945918795168","article-title":"Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching","volume":"7","author":"Jorgensen","year":"2019","journal-title":"J. Mark. Access Health Policy"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1500419","DOI":"10.1080\/20016689.2018.1500419","article-title":"The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson\u2019s disease","volume":"6","author":"Jorgensen","year":"2018","journal-title":"J. Mark. Access Health Policy"},{"key":"B87","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jval.2019.01.001","article-title":"Managing risk and uncertainty in health technology introduction: the role of managed entry agreements","volume":"8","author":"Kanavos","year":"2017","journal-title":"Global Policy"},{"key":"B88","doi-asserted-by":"publisher","first-page":"63","DOI":"10.18553\/jmcp.2020.26.1.63","article-title":"Examining misaligned incentives for payers and manufacturers in value-based pharmaceutical contracts","volume":"26","author":"Kannarkat","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B89","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial","volume":"318","author":"Kazi","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1511679","DOI":"10.1080\/20016689.2018.1511679","article-title":"Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy","volume":"6","author":"Kefalas","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/20016689.2018.1511679","article-title":"The future of pharmacoeconomic policy - does value-based pricing really have a role?","volume":"7","author":"Kiernan","year":"2016","journal-title":"J. Pharmaceut. Health Serv. Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40545-018-0131-4","article-title":"A real world example of coverage with evidence development in Australia - Ipilimumab for the treatment of metastatic melanoma","volume":"11","author":"Kim","year":"2018","journal-title":"J. Pharm. Policy Pract."},{"key":"B93","first-page":"118","article-title":"Breaking the bank: three financing models for addressing the drug innovation cost crisis","volume":"8","author":"Kleinke","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"B94","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S0266462310001297","article-title":"What principles should govern the use of managed entry agreements?","volume":"27","author":"Klemp","year":"2011","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B95","doi-asserted-by":"publisher","first-page":"A689","DOI":"10.1016\/j.jval.2015.09.2554","article-title":"The cost of treatment of the new antiviral therapies against the hepatitis C virus","volume":"18","author":"Kocsis","year":"2015","journal-title":"Value Health"},{"key":"B96","doi-asserted-by":"publisher","first-page":"A487","DOI":"10.1016\/j.jval.2013.08.957","article-title":"Coverage with evidence development in Sweden - formality or effective way to reduce uncertainty?","volume":"16","author":"Kornfeld","year":"2013","journal-title":"Value Health"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3111\/13696998.2013.823868","article-title":"Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment","volume":"16","author":"Lage","year":"2013","journal-title":"J. Med. Econ."},{"key":"B98","doi-asserted-by":"publisher","first-page":"24988","DOI":"10.3402\/jmahp.v2.24988","article-title":"Health economic value of an innovation: delimiting the scope and framework of future market entry agreements","volume":"2","author":"Launois","year":"2014","journal-title":"J. Mark. Access Health Policy"},{"key":"B99","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2015.61.2838","article-title":"Coverage with evidence development and managed entry in the funding of personalized medicine: practical and ethical challenges for oncology","volume":"33","author":"Lewis","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"A449","DOI":"10.1016\/j.jval.2014.08.1203","article-title":"Coverage with evidence development activities around the world: an environment scan","volume":"17","author":"Li","year":"2014","journal-title":"Value Health"},{"key":"B101","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/j.jval.2018.04.619","article-title":"New drugs approval in Italy: updated analysis of the applied negotiation conditions 2015\u20132017","volume":"21","author":"Lidonnici","year":"2018","journal-title":"Value Health"},{"key":"B102","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13561-019-0242-x","article-title":"Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists","volume":"9","author":"Lorente","year":"2019","journal-title":"Health Econ. Rev."},{"key":"B103","doi-asserted-by":"publisher","first-page":"A30","DOI":"10.1111\/j.1365-2125.2010.03740.x","article-title":"Value based pricing: what is the future for patient access schemes?","volume":"14","author":"Loveman","year":"2011","journal-title":"Value Health"},{"key":"B104","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40545-014-0019-x","article-title":"Patient access schemes in Asia-pacific markets: current experience and future potential","volume":"8","author":"Lu","year":"2015","journal-title":"J. Pharm. Policy Pract."},{"key":"B105","doi-asserted-by":"crossref","first-page":"A243","DOI":"10.1016\/S1098-3015(10)74187-5","article-title":"The usefulness and challenges of patient cess (risk sharing) schemes in the UK","volume":"12","author":"Lucas","year":"2009","journal-title":"Value Health"},{"key":"B106","doi-asserted-by":"crossref","first-page":"A568","DOI":"10.1016\/j.jval.2015.09.1870","article-title":"Payer vs. industry views on managed entry agreements","volume":"18","author":"Lucas","year":"2015","journal-title":"Value Health"},{"key":"B107","doi-asserted-by":"publisher","first-page":"A403","DOI":"10.1016\/j.jval.2017.08.034","article-title":"Innovative pricing and reimbursement schemes-the what , why, which, and how","volume":"20","author":"Macaulay","year":"2017","journal-title":"Value Health"},{"key":"B108","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/j.jval.2019.04.1376","article-title":"PNS10 innovative pharmaceutical pricing and reimbursement schemes in the US, a cautionary tales from abroad","volume":"22","author":"Macaulay","year":"2019","journal-title":"Value Health"},{"key":"B109","volume-title":"Innovative solutions for paradigm changing new therapies \u2013 policy report based on multi-stakeholder round tables.","author":"Maes","year":"2019"},{"key":"B110","first-page":"70","article-title":"Value-based arrangements may be more prevalent than assumed","volume":"25","author":"Mahendraratnam","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"B111","doi-asserted-by":"publisher","first-page":"888","DOI":"10.7326\/M18-0539","article-title":"Money-back guarantees for expensive drugs: wolf's clothing but a sheep underneath","volume":"168","author":"Mailankody","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jval.2018.11.016","article-title":"Conditional financing of drugs in The The Netherlands: past, present, and future-results from stakeholder interviews","volume":"22","author":"Makady","year":"2019","journal-title":"Value Health"},{"key":"B113","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.healthpol.2018.09.016","article-title":"Implementing managed entry agreements in practice: the Dutch reality check","volume":"123","author":"Makady","year":"2019","journal-title":"Health Policy"},{"key":"B114","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2217\/rme-2016-0014","article-title":"Pay-for-performance pricing for a breakthrough heart drug: learnings for cell and gene therapies","volume":"11","author":"Malik","year":"2016","journal-title":"Regen. Med."},{"key":"B115","article-title":"Gene therapy: understanding the science, assessing the evidence, and paying for value","author":"Marsden","year":"2017"},{"key":"B116","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.vhri.2018.04.003","article-title":"Managed entry agreements for pharmaceutical products in Middle East and north african countries: payer and manufacturer experience and outlook","volume":"16","author":"Maskineh","year":"2018","journal-title":"Value Health Reg. Issues"},{"key":"B117","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/11530850-000000000-00000","article-title":"Access with evidence development schemes: a framework for description and evaluation","volume":"28","author":"McCabe","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"B118","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1016\/j.jval.2018.09.1248","article-title":"PHP354 - the impact of data privacy regulations on drug utilization data sharing for innovative pricing arrangements","volume":"21","author":"Menner","year":"2018","journal-title":"Value Health"},{"key":"B119","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/11530860-000000000-00000","article-title":"Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit","volume":"28","author":"Menon","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"B120","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.hcmf.2011.02.008","article-title":"Access with evidence development: an approach to introducing promising new technologies into healthcare","volume":"24","author":"Menon","year":"2011","journal-title":"Health Manage. Forum"},{"key":"B121","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jval.2014.10.008","article-title":"Evaluation of patient registries supporting reimbursement decisions: the case of oxaliplatin for treatment of stage III colon cancer","volume":"18","author":"Mohseninejad","year":"2015","journal-title":"Value Health"},{"key":"B122","doi-asserted-by":"publisher","first-page":"327ps6","DOI":"10.1126\/scitranslmed.aad6913","article-title":"Buying cures versus renting health: financing health care with consumer loans","volume":"8","author":"Montazerhodjat","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1017\/S0266462315000446","article-title":"Monitoring registries at Italian medicines agency: fostering access, guaranteeing sustainability","volume":"31","author":"Montilla","year":"2015","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B124","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.18553\/jmcp.2020.26.4.529","article-title":"A discrete choice experiment on payer preferences for innovative payment schemes aimed at financing high-cost, potentially curative therapies","volume":"25","author":"Moradi","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B125","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1750-1172-8-198","article-title":"Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries","volume":"8","author":"Morel","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"B126","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1017\/S026646231900031X","article-title":"Improving access to high-cost technologies in the asia region","volume":"35","author":"Mundy","year":"2019","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B127","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2014.09.007","article-title":"Do the current performance-based schemes in Italy really work? \u201cSuccess fee\u201d: a novel measure for cost-containment of drug expenditure","volume":"18","author":"Navarria","year":"2015","journal-title":"Value Health"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.18553\/jmcp.2017.23.10.1018","article-title":"Outcomes-based contracting experience: research findings from U.S. and European stakeholders","volume":"23","author":"Nazareth","year":"2017","journal-title":"J. Manage. Care Spec. Pharm."},{"key":"B129","volume-title":"Moving forward on value-based contracting for biopharmaceuticals","year":"2017"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1377\/hlthaff.2010.1147","article-title":"Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement","volume":"30","author":"Neumann","year":"2011","journal-title":"Health Aff."},{"key":"B131","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.jval.2018.09.488","article-title":"PCP13 - impact of outcome based annuities on small BioTech companies","volume":"21","author":"Nevins","year":"2018","journal-title":"Value Health"},{"key":"B132","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0735-1097(18)32294-0","article-title":"Cost effectiveness of an outcome based reimbursement model of PCSK9 inhibitors","volume":"71","author":"Oren","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1744133119000288","article-title":"Physicians\u2019 attitudes towards accelerated access to medicines","author":"Pace","year":"2019","journal-title":"Health Econom. Policy Law"},{"key":"B134","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/J.JVAL.2019.04.110","article-title":"PBI28 novel managed care strategies can improve access to cellular and gene therapy products","volume":"22","author":"Patel","year":"2019","journal-title":"Value Health"},{"key":"B135","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fphar.2017.00171","article-title":"Managed entry agreements for oncology drugs: lessons from the European experience to inform the future","volume":"8","author":"Pauwels","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B136","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.jval.2018.04.812","article-title":"Agreement between FDA approved drug label and performance-based risk-sharing arrangement endpoints","volume":"21","author":"Pham","year":"2018","journal-title":"Value Health"},{"key":"B137","unstructured":"Medical breakthroughs and credit markets: forbes\n            PhilipsonT.\n          2014"},{"key":"B138","doi-asserted-by":"publisher","first-page":"A756","DOI":"10.1016\/j.jval.2016.09.2339","article-title":"Role of clinical pharmacist in optimizing reimbursement originating from performance-based risk-sharing arrangements: the experience of the university hospital \u201cG. Martino\u201d from Messina, Italy","volume":"19","author":"Polimeni","year":"2016","journal-title":"Value Health"},{"key":"B139","doi-asserted-by":"publisher","first-page":"A750","DOI":"10.1016\/j.jval.2016.09.2305","article-title":"Missed opportunities in The Netherlands: the negligence of non-statistical uncertainty in CED policy","volume":"19","author":"Pouwels","year":"2016","journal-title":"Value Health"},{"key":"B140","doi-asserted-by":"publisher","first-page":"A568","DOI":"10.1016\/j.jval.2015.09.1868","article-title":"A review of guidelines and approaches to performance-based risk-sharing agreements across the UK, Italy and The Netherlands","volume":"18","author":"Pritchett","year":"2015","journal-title":"Value Health"},{"key":"B141","doi-asserted-by":"publisher","first-page":"A258","DOI":"10.1016\/j.jval.2016.03.1879","article-title":"Exploring alternative payment methodologies for innovative, expensive treatments: what is needed to trigger a change from the current upfront payment system?","volume":"19","author":"Proach","year":"2016","journal-title":"Value Health"},{"key":"B142","doi-asserted-by":"crossref","first-page":"A243","DOI":"10.1016\/j.jval.2011.08.069","article-title":"Literature review on patient access schemes, flexible pricing schemes and risk sharing agreements for medicines","volume":"14","author":"Puig-Peir\u00f3","year":"2011","journal-title":"Value Health"},{"key":"B143","volume-title":"Launching into value: pharma\u2019s quest to align drug prices with outcomes","year":"2017"},{"key":"B144","doi-asserted-by":"publisher","first-page":"c1672","DOI":"10.1136\/bmj.c1672","article-title":"Multiple sclerosis risk sharing scheme: a costly failure","volume":"340","author":"Raftery","year":"2010","journal-title":"BMJ"},{"key":"B145","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.jval.2018.09.485","article-title":"Patient access to new medicines; the changing landscape","volume":"21","author":"Richardson","year":"2018","journal-title":"Value Health"},{"key":"B146","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1017\/S0266462317001106","article-title":"Characteristics of managed entry agreements in Australia","volume":"34","author":"Robinson","year":"2018","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B147","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1215\/03616878-4249796","article-title":"Innovative contracting for pharmaceuticals and medicaid's best-price rule","volume":"43","author":"Sachs","year":"2018","journal-title":"J. Health Polit. Policy Law"},{"key":"B148","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","article-title":"Addressing the value of gene therapy and enhancing patient access to transformative treatments","volume":"26","author":"Salzman","year":"2018","journal-title":"Mol. Ther."},{"key":"B149","first-page":"A143","article-title":"Pearls and pitfalls of performance-linked reimbursement plans for novel drugs: the case of sacubitril-valsartan","volume":"11","author":"Sandhu","year":"2018","journal-title":"Circulation"},{"key":"B150","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jval.2017.12.013","article-title":"Paying for cures: perspectives on solutions to the \u201caffordability issue\u201d","volume":"21","author":"Schaffer","year":"2018","journal-title":"Value Health"},{"key":"B151","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/j.jval.2018.09.881","article-title":"Darvadstrocel in the management of complex perianal fistulas: the role of patient registry data collection to support performance-based risk sharing agreements","volume":"21","author":"Schmetz","year":"2018","journal-title":"Value Health"},{"key":"B152","volume-title":"Outcomes-based pharmaceutical contracts: an answer to high U.S. drug spending?","author":"Seeley","year":"2017"},{"key":"B153","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nbt0418-291a","article-title":"Rollout of high-priced cell and gene therapies forces payer rethink","volume":"36","author":"Senior","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B154","volume-title":"New payment and financing models for curative regenerative medicines","author":"Slocomb","year":"2017"},{"key":"B155","doi-asserted-by":"publisher","first-page":"A685","DOI":"10.1016\/j.jval.2017.08.1729","article-title":"Paying for gene therapies: approaching a sustainable solution","volume":"20","author":"Spark","year":"2017","journal-title":"Value Health"},{"key":"B156","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11530820-000000000-00000","article-title":"Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems","volume":"28","author":"Stafinski","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"B157","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13023-018-0791-9","article-title":"Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID","volume":"13","author":"Stirnadel-Farrant","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"B158","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/bmj.326.7385.388","article-title":"Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis","volume":"326","author":"Sudlow","year":"2003","journal-title":"BMJ"},{"key":"B159","doi-asserted-by":"publisher","first-page":"A420","DOI":"10.1016\/S1098-3015(11)72750-4","article-title":"Successful implementation of coverage with evidence development schemes: practical experiences in several western jurisdictions","volume":"13","author":"Theunissen","year":"2010","journal-title":"Value Health"},{"key":"B160","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/CEOR.S96616","article-title":"Targeting improved patient outcomes using innovative product listing agreements: a survey of canadian and international key opinion leaders","volume":"8","author":"Thompson","year":"2016","journal-title":"Clin. Outcomes Res."},{"key":"B161","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/nbt.3003","article-title":"The payers\u2019 perspective on gene therapies","volume":"33","author":"Touchot","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/genes8020078","article-title":"Early insights from commercialization of gene therapies in Europe","volume":"8","author":"Touchot","year":"2017","journal-title":"Genes"},{"key":"B163","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40258-016-0274-x","article-title":"The use of surrogate and patient-relevant endpoints in outcomes-based market access agreements: current debate","volume":"15","author":"Toumi","year":"2017","journal-title":"Appl. Health Econ. Health Pol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jval.2019.03.013","article-title":"Uncertainty and cures: discontinuation, irreversibility, and outcomes-based payments: what is different about a one-off treatment?","volume":"22","author":"Towse","year":"2019","journal-title":"Value Health"},{"key":"B165","volume-title":"The use of pay-for-performance for drugs: can it improve incentives for innovation?","author":"Towse","year":"2012"},{"key":"B166","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/11314080-000000000-00000","article-title":"Can\u2019t get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products","volume":"28","author":"Towse","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"B167","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1017\/S0266462309990882","article-title":"Coverage with evidence development: applications and issues","volume":"26","author":"Trueman","year":"2010","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B168","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40273-018-0633-6","article-title":"The Australian managed entry scheme: are we getting it right?","volume":"36","author":"Tuffaha","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"B169","doi-asserted-by":"publisher","first-page":"A415","DOI":"10.1016\/j.jval.2014.08.1000","article-title":"Availability of risk sharing agreements in the Turkish pharmaceutical sector","volume":"17","author":"Tuna","year":"2014","journal-title":"Value Health"},{"key":"B170","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/j.jval.2018.09.1243","article-title":"The evolution of standard monitoring registries in the Italian market","volume":"21","author":"Urbinati","year":"2018","journal-title":"Value Health"},{"key":"B171","volume-title":"Developing a Path to value-based payment for medical products: value-based payment advisory group kick-off meeting","year":"2017"},{"key":"B172","doi-asserted-by":"publisher","first-page":"A499","DOI":"10.1016\/j.jval.2016.09.885","article-title":"Success and failure of straightforward versus sophisticated managed entry agreements","volume":"19","author":"Van De Vijver","year":"2016","journal-title":"Value Health"},{"key":"B173","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jval.2016.09.001","article-title":"The challenge of conditional reimbursement: stopping reimbursement can Be more difficult than not starting in the first place!","volume":"20","author":"van de Wetering","year":"2017","journal-title":"Value Health"},{"key":"B174","doi-asserted-by":"publisher","first-page":"A376","DOI":"10.1016\/j.jval.2016.09.001","article-title":"The first experiences with reassessments and appraisals of conditionally approved expensive and orphan drugs in The Netherlands (2006\u20132013)","volume":"16","author":"Van Der Meijden","year":"2013","journal-title":"Value Health"},{"key":"B175","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.healthpol.2014.05.005","article-title":"Managed entry agreements for pharmaceuticals in Australia","volume":"117","author":"Vitry","year":"2014","journal-title":"Health Policy"},{"key":"B176","article-title":"Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward","author":"Wenzl","year":"2019"},{"key":"B177","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/annonc\/mdx110","article-title":"Patient access schemes for high-cost cancer medicines","volume":"11","author":"Williamson","year":"2010","journal-title":"Lancet Oncol."},{"key":"B178","first-page":"268","article-title":"A report into the uptake of patient access schemes in the NHS","volume":"2","author":"Williamson","year":"2010","journal-title":"Clin. Pharm."},{"key":"B179","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1179\/1757092112Z.0000000009","article-title":"The Italian post-marketing registries","volume":"5","author":"Xoxi","year":"2012","journal-title":"Pharmaceut. Program."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.18553\/jmcp.2017.23.10.1010","article-title":"Using performance-based risk-sharing arrangements to address uncertainty in indication-based pricing","volume":"23","author":"Yeung","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.18553\/jmcp.2017.23.10.1084","article-title":"Paying for cures: how can we afford it? Managed care pharmacy stakeholder perceptions of policy options to address affordability of prescription drugs","volume":"23","author":"Yeung","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.18553\/jmcp.2017.23.10.1028","article-title":"Performance-based risk-sharing arrangements for pharmaceutical products in the United States: a systematic review","volume":"23","author":"Yu","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.594446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T02:08:13Z","timestamp":1607393293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.594446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":182,"alternative-id":["10.3389\/fphar.2020.594446"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.594446","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]},"article-number":"594446"}}